Market Place
Sourcing Support
Novartis Completes Acquisition of Avidity Biosciences
27 Feb 2026 //
GLOBENEWSWIRE
Atrium Arises From Avidity Buyout With $270M, Preclinical Assets
27 Feb 2026 //
FIERCE BIOTECH
Avidity Biosciences to Adjourn Special Meeting
23 Feb 2026 //
PR NEWSWIRE
New England Journal Of Medicine Releases MARINA Trial Phase 1/2
18 Feb 2026 //
PR NEWSWIRE
Avidity Biosciences Launches U.S. Managed Access Program
19 Nov 2025 //
PR NEWSWIRE
Avidity Biosciences Unveils Q3 2025 Financials & Highlights
11 Nov 2025 //
PR NEWSWIRE
Novartis Bolsters Neuromuscular Pipeline Via $12B Avidity Buyout
27 Oct 2025 //
BIOSPACE
Avidity Biosciences Joins Investor Conference
16 Oct 2025 //
PR NEWSWIRE
Avidity Biosciences Closes Upsized Public Offering
15 Sep 2025 //
PR NEWSWIRE
Avidity Biosciences Prices Upsized Public Stock Offering
11 Sep 2025 //
PR NEWSWIRE
Avidity Biosciences Proposes Public Common Stock Offering
11 Sep 2025 //
PR NEWSWIRE
Avidity Biosciences Joins Investor Conferences
27 Aug 2025 //
PR NEWSWIRE
Novartis Weighs Deal for Biotech Avidity Biosciences
09 Aug 2025 //
REUTERS
Avidity Bio Completes Enrollment for Harbor Phase 3 Trial
28 Jul 2025 //
PR NEWSWIRE
Avidity Gets FDA Nod for Delpacibart Zotadirsen in DMD
23 Jul 2025 //
PR NEWSWIRE
Avidity Starts Ph3 FORWARD Study for Del-Brax in FSHD
09 Jun 2025 //
PR NEWSWIRE
Avidity Ph1/2 Data Shows Del-Brax Improved FSHD Outcomes
09 Jun 2025 //
PR NEWSWIRE
Avidity Biosciences Reports Q1 2025 Financial Results
08 May 2025 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
21 Apr 2025 //
PR NEWSWIRE
Avidity Biosciences Announces Grants Under Nasdaq LR 5635(c)(4)
08 Jan 2025 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
20 Dec 2024 //
PR NEWSWIRE
Avidity Bio to Host Investor Event on Precision Cardiology Nov 12
31 Oct 2024 //
PR NEWSWIRE
Avidity Accelerate Approval in Fortitude Facioscapulohumeral MD
30 Oct 2024 //
PR NEWSWIRE
Avidity Announce FDA Lifts Partial Hold On Del-desiran Program
03 Oct 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Inducement Grants
23 Sep 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Inducement Grants
21 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences Closes Upsized Public Offering With Full Option
19 Aug 2024 //
PR NEWSWIRE
Avidity`s AOC 1044 Shows Positive Data In Duchenne Muscular Dystrophy Trial
09 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences Reports Q2 2024 Results And Recent Highlights
09 Aug 2024 //
PR NEWSWIRE
Avidity Appoints John B. Moriarty, Jr. As Chief Legal Officer
05 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Inducement Grants
05 Aug 2024 //
PR NEWSWIRE
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
12 Jun 2024 //
PR NEWSWIRE
Avidity Presents Prelim FORTITUDE Data On AOC 1020 In FSHD
29 May 2024 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq Rule
21 May 2024 //
PR NEWSWIRE
Avidity Biosciences Appoints Simona Skerjanec To Board Of Directors
15 May 2024 //
PR NEWSWIRE
Avidity Biosciences Q1 2024 Financials, Highlights
09 May 2024 //
PR NEWSWIRE
Avidity Gets FDA Breakthrough Status For Dystrophy Drug
08 May 2024 //
PR NEWSWIRE
Avidity Bio Announces Nasdaq Inducement Grants
22 Apr 2024 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Mar 2024 //
PR NEWSWIRE
Avidity Biosciences Announces Positive AOC 1001 Long-term Data
04 Mar 2024 //
PR NEWSWIRE
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044
20 Feb 2024 //
PR NEWSWIRE
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data
15 Feb 2024 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Jan 2024 //
PR NEWSWIRE
Avidity Bio Announces 2024 Corporate Priorities
05 Jan 2024 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Dec 2023 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Nov 2023 //
PR NEWSWIRE
Avidity Biosciences Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 Oct 2023 //
PR NEWSWIRE
Avidity Announces AOC 1001 Data Showing Improvement in Functional Endpoints
07 Oct 2023 //
PR NEWSWIRE
Avidity Biosciences Announces Upcoming Presentations at Muscle Society
26 Sep 2023 //
PR NEWSWIRE
Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Sep 2023 //
PR NEWSWIRE
Avidity Biosciences Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing
21 Jun 2023 //
PR NEWSWIRE
Avidity Biosciences Joins with Patients, Caregivers & Healthcare Globally
20 Jun 2023 //
PR NEWSWIRE
Avidity Biosciences Announces Presentations at 30th Annual FSHD Society Congress
08 Jun 2023 //
PR NEWSWIRE
Avidity Biosciences Reports1Q 2023 FYR and Recent Highlights
09 May 2023 //
PR NEWSWIRE
Avidity Biosciences Announces Positive Topline Data from AOC 1001 Ph1/2 MARINA™
27 Apr 2023 //
PR NEWSWIRE
Avidity to Host Event Focused on AOC 1001 Data from Phase 1/2 MARINA Trial
13 Apr 2023 //
PR NEWSWIRE
Avidity Biosciences Provides Regulatory Update on AOC 1001
30 Mar 2023 //
PR NEWSWIRE
Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Mar 2023 //
PR NEWSWIRE
